Cytarabine dose for acute myeloid leukemia.

Löwenberg, Bob;Pabst, Thomas;Vellenga, Edo;van Putten, Wim;Ossenkoppele, Gert J;et.al.
(2011) The New England journal of medicine — Vol. 364, n° 11, p. 1027-1036 (2011)

Files

Svrshare1cvmedecinsDIALHématoGrauxNEJM2011.pdf
  • Closed Access
  • Adobe PDF
  • 520.32 KB
Request a copy
LowenbergBetalCytarabine-NEJM2011.pdf
  • Restricted Access
  • Adobe PDF
  • 520.48 KB
Request a copy

Details

Authors
  • Löwenberg, Bob
    Author
  • Pabst, Thomas
    Author
  • Vellenga, Edo
    Author
  • van Putten, Wim
    Author
  • Graux, CarlosUCLouvain
    Author
  • Ossenkoppele, Gert J
    Author
Show more
Abstract
Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B. J., Gratwohl, A., de Greef, G. E., Verdonck, L. F., Schaafsma, M. R., Gregor, M., Theobald, M., Schanz, U., Maertens, J., & Ossenkoppele, G. J. (2011). Cytarabine dose for acute myeloid leukemia. The New England journal of medicine, 364(11), 1027-1036. https://doi.org/10.1056/NEJMoa1010222 (Original work published 2011)